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The relationship between alternans and arrhythmogenicity was studied in genetically modified 
murine hearts modeling catecholaminergic polymorphic ventricular tachycardia (CPVT) during 
Langendorff perfusion, before and after treatment with catecholamines and a β-adrenergic 
antagonist. Heterozygous (RyR2p/s) and homozygous (RyR2s/s) RyR2-P2328S hearts, and wild-type 
(WT) controls, were studied before and after treatment with epinephrine (100 nM and 1 μM) and 
propranolol (100 nM). Monophasic action potential recordings demonstrated significantly greater 
incidences of arrhythmia in RyR2s/p and RyR2s/s hearts as compared to WTs. Arrhythmogenicity 
in RyR2s/s hearts was associated with alternans, particularly at short baseline cycle lengths. Both 
phenomena were significantly accentuated by treatment with epinephrine and significantly 
diminished by treatment with propranolol, in full agreement with clinical expectations. These 
changes took place, however, despite an absence of changes in mean action potential durations, 
ventricular effective refractory periods or restitution curve characteristics. Furthermore pooled 
data from all hearts in which arrhythmia occurred demonstrated significantly greater alternans 
magnitudes, but similar restitution curve slopes, to hearts that did not demonstrate arrhythmia. 
These findings thus further validate the RyR2-P2328S murine heart as a model for human CPVT, 
confirming an alternans phenotype in common with murine genetic models of the Brugada 
syndrome and the congenital long-QT syndrome type 3. In contrast to these latter similarities, 
however, this report demonstrates the dissociation of alternans from changes in the properties 
of restitution curves for the first time in a murine model of a human arrhythmic syndrome.
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FKBP12.6 binding following PKA phosphorylation in HEK293 cells 
(Lehnart et al., 2004). Mice genetically modified to lack FKBP12.6 
and proposed as a model for CPVT demonstrate arrhythmia in 
association with alternans in action potential duration (APD) 
(Lehnart et al., 2006); both these phenomena could be prevented 
by pharmacological maneuvers expected to increase the binding 
affinity of FKBP12.6 for RyR2. Such associations between alternans 
and ventricular arrhythmia are well established in both histori-
cal and contemporary literature (Lewis, 1911; Gold et al., 2000; 
Weiss et al., 2006), with electrocardiographic alternans having been 
reported in carriers of mutations associated with CPVT (Aizawa 
et al., 2006).
The present study extends correlations between alternans and 
arrhythmia (Weiss et al., 2006) to genetically modified hearts car-
rying the P2328S mutation and thus representing a true genetic 
model of CPVT (Goddard et al., 2008). It thus: (1) confirms previ-
ous reports of elevated incidences of arrhythmia in RyR2-P2328S 
hearts as compared to wild-type (WT) controls (Goddard et al., 
INTRODUCTION
Catecholaminergic polymorphic ventricular tachycardia (CPVT) 
is a hereditary arrhythmic disorder characterized by ventricular 
tachyarrhythmias precipitated by exercise, stress or catecholamine 
infusion (Wehrens et al., 2003). Such arrhythmias may potentially 
lead to ventricular fibrillation, resulting in syncope and sudden 
cardiac death (Priori et al., 2001). CPVT is a highly lethal condition, 
with Kaplan Meyer analyses confirming mortality rates of 30–33% 
by age 35 (Priori et al., 2001). Current therapies are unsatisfactory 
but include regular administration of β-adrenoceptor antagonists 
(Leenhardt et al., 1995) and insertion of automatic implantable 
cardioverter defibrillators (Priori et al., 2001).
CPVT is associated with mutations in the cardiac ryanodine 
receptor (RyR2) (Marks et al., 2002). Six distinct RyR2 mutations, 
occurring in the absence of structural abnormalities, echocardio-
graphic evidence of cardiac failure or QT prolongation, have been 
reported to result in CPVT (Laitinen et al., 2001; Priori et al., 2001). 
Of these, a hereditary P2328S mutation has been shown to alter 
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A bipolar platinum stimulating electrode (1 mm inter-pole 
 spacing) was placed against the basal surface of the right ventricu-
lar epicardium. Square-wave stimuli (Grass S48 stimulator, Grass-
Telefactor, Slough, UK) of 2-ms duration and amplitudes of twice 
the diastolic excitation threshold were initially applied to hearts at 
a constant baseline cycle length (BCL) of 125 ms. Recordings met 
quality assurance criteria defined previously, with one action poten-
tial occurring in response to each stimulus, each action potential 
demonstrating a rapid upstroke phase that reached a consistent 
amplitude and a smooth re-polarization phase and the baseline 
remaining stable between action potentials (Knollmann et al., 2001; 
Fabritz et al., 2003). APD was quantified at 90% re-polarization 
(APD
90
), APD
0
 being defined as the peak upstroke potential dif-
ference and APD
100
 as the diastolic potential difference. Notably, 
inclusion or exclusion of the upstroke phase did not make a signifi-
cant (P > 0.05) difference to results under any set of experimental 
conditions studied. Before subsequent recordings were made hearts 
were then exposed to test solutions for 10 min while stimulation 
was continued.
MAPs were recorded during regular stimulation at a BCL of 85, 
95, 105, 115, and 125 ms and the data obtained used to assess the 
magnitude of alternans present. Such alternans was defined as a 
sequence of ten or more action potentials the duration of which 
were shorter then longer (or vice versa) than in the previous beat. 
A detection margin of 0.2 ms was used, reflecting the sampling 
sensitivity of the Spike II data acquisition software utilized. An 
extrasystolic stimulation protocol (Saumarez and Grace, 2000) pre-
viously adapted for use in murine hearts (Head et al., 2005) was 
then applied. This comprised regular stimuli delivered at a BCL 
of 125 ms interrupted by extrasystolic stimuli imposed after every 
eighth regular stimulus at delays progressively decremented with 
each successive stimulus cycle in 1 ms steps from the BCL. Such 
cycles were repeated until the extrasystolic stimuli either initiated 
arrhythmia or failed to initiate a MAP, the ventricular effective 
refractory period (VERP) having been reached. Hearts were then 
subjected to an adapted dynamic pacing protocol (Koller et al., 1998; 
Sabir et al., 2008b). This comprised cycles each of 100 stimuli, 
initially delivered at a BCL of 175 ms. BCL was decremented in 
5 ms steps with each successive stimulus cycle until a reproducible 
sequence of consistently shaped MAP waveforms was no longer 
obtained. This dynamic pacing protocol was also used to induce 
arrhythmia, with arrhythmia being defined as a > 5 s period of 
morphologically irregular waveforms continuing in the absence 
of stimulation.
Recordings were made in the absence of pharmacological 
agents, following addition of epinephrine, following addition of 
propranolol, and following addition of both epinephrine and pro-
pranolol. Hearts were exposed to reagent-containing solutions for 
10 min during stimulation at a constant BCL of 125 ms before data 
were collected.
All data are presented as means ± standard errors of the means 
and include the numbers of hearts studied. Comparisons between 
data sets used analysis of variance (ANOVA) and the Chi-squared 
test to make multiple comparisons between continuous and dis-
crete data respectively (significance thresholds set at P ≤ 0.05). 
A Levenberg–Marquardt algorithm (OriginPro 7.5, OriginLab, 
Northampton, MA, USA) was used for curve fitting.
2008); (2) correlates such arrhythmogenicity with a tendency to 
exhibit alternans, in agreement with observations both in humans 
with CPVT (Aizawa et al., 2006) and in murine genetic models 
of other hereditary arrhythmic syndromes and (3) demonstrates 
that treatment with adrenergic agonists and antagonists, known to 
be pro- and anti-arrhythmic respectively in humans with CPVT 
(Leenhardt et al., 1995), suppresses and accentuates alternans as 
might be expected. It then proceeds to demonstrate that such alter-
nans occurs in the absence of changes in either (4) mean action 
potential properties, (5) refractory periods or (6) restitution curve 
characteristics, in sharp contrast to findings in those other murine 
models (Sabir et al., 2008a).
MATERIALS AND METHODS
Genetically modified mice heterozygous (RyR2p/s) and homozygous 
(RyR2s/s) for the P2328S mutation in the central region of the RyR2 
gene (Goddard et al., 2008), along with WT controls, were housed in 
an animal facility at 21 ± 1°C with 12-h light/dark cycles. All mice 
were fed sterile chow (RM3 Maintenance Diet, SDS, Witham, Essex, 
UK) and given free access to water. All procedures were carried out 
in accordance with the UK Animals (Scientific Procedures) Act 
1986. Bicarbonate-buffered Krebs–Henseleit solutions (119 mM 
NaCl, 25 mM NaHCO
3
, 4 mM KCl, 1.2 mM KH
2
PO
4
, 1 mM MgCl
2
, 
1.8 mM CaCl
2
, 10 mM glucose and 2 mM Na-pyruvate) were 
used. These were bubbled with 95% O
2
/5% CO
2
 (British Oxygen 
Company, Manchester, UK) to achieve a physiological pH of 7.4 and 
prevent the precipitation of calcium carbonate. Drug-containing 
solutions were prepared by adding epinephrine (Sigma-Aldrich, 
Poole, UK) to final concentrations of either 100 nM or 1 μM as 
stated and propranolol (Sigma-Aldrich, Poole, UK) to a final con-
centration of 100 nM, as used on previous occasions (Tosaka et al., 
2003; Thomas et al., 2007a).
A Langendorff-perfusion protocol previously validated for use 
with murine hearts (Balasubramaniam et al., 2003) was used. In brief, 
mice were killed by cervical dislocation (Schedule 1: UK Animals 
[Scientific Procedures] Act 1986). Hearts were then quickly excised 
and placed in ice-cold bicarbonate-buffered Krebs–Henseleit solu-
tion. Short sections of aorta were then rapidly cannulated under 
the surface of the ice-cold buffer solution and attached using an 
aneurysm clip (Harvard Apparatus, Edenbridge, Kent, UK) to a 
custom-made 21-gauge cannula. Fresh Krebs–Henseleit solution 
was passed through 200 and 5 μm filters (Millipore, Watford, UK) 
and warmed to 37ºC using a water jacket and circulator (Techne 
model C-85A, Cambridge, UK). A peristaltic pump (Watson-
Marlow Bredel model 505S, Falmouth, Cornwall, UK) in constant 
flow mode was then used to perfuse hearts with this solution at 
2–2.5 ml/min in a retrograde fashion. Hearts were regarded as suit-
able for experimentation if they regained a healthy pink color and 
began to contract spontaneously on re-warming.
An epicardial monophasic action potential (MAP) electrode 
(Hugo Sachs, Harvard Apparatus, UK) was placed against the 
basal left ventricular epicardium. Signals were amplified, band-
pass filtered (0.5 Hz to 1 kHz: Neurolog, Digitimer, Welwyn Garden 
City, Hertfordshire, UK) and digitized at a sampling frequency of 
5 kHz (micro1401, Cambridge Electronic Design, Cambridge, UK). 
Data analysis was performed using Spike II (Cambridge Electronic 
Design, Cambridge, UK).
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incidence of  arrhythmia with mutant gene dosage in RyR2-P2328S 
mice (Goddard et al., 2008), as well as the pro-arrhythmic and anti-
arrhythmic effects of epinephrine and propranolol respectively.
The experiments then demonstrated alternans in RyR2-P2328S 
hearts for the first time, a finding in full agreement with clinical 
reports (Aizawa et al., 2006). Figure 3 plots alternans magnitude, 
the mean difference in APD (quantified at 90% re-polarization, 
APD
90
) between successive odd- and even-numbered action poten-
tials, against BCL. Hearts were studied before (diamonds) and after 
addition of 100 nM (squares) or 1 μM (triangles) epinephrine both 
before (Figure 3, top panel) and after (Figure 3, bottom panel) intro-
duction of propranolol. Alternans magnitude tended to increase with 
decreasing BCL in agreement with previous findings (Walker et al., 
2003), yielding significantly larger values at the shortest (85 ms) as 
compared to the longest (125 ms, P < 0.05) BCLs studied under all 
conditions. All subsequent comparisons between alternans magni-
tudes were made using data obtained at a BCL of 85 ms.
WT hearts demonstrated alternans only at the shortest BCL 
studied, as in previous reports (Sabir et al., 2008b). Exposure 
to epinephrine, whether at concentration of 100 nM or 1 μM, 
significantly (P < 0.05) increased alternans magnitude. Before 
RESULTS
The experiments first confirmed the presence or absence of arrhyth-
mogenic phenomena in intact Langendorff-perfused WT murine 
hearts, as well as in hearts heterozygous (RyR2p/s) and homozygous 
(RyR2s/s) for a mutation known to result in CPVT in humans. 
This confirmed and extended previous reports of an increase in 
incidence of arrhythmia with gene dosage in RyR2-P2328S mice 
(Goddard et al., 2008) using a dynamic pacing protocol.
Figure 1 gives incidences of arrhythmia in WT, RyR2p/s and 
RyR2s/s hearts under the various pharmacological and stimulation 
conditions employed. Figure 2 illustrates the recordings obtained, 
summarizing these results by showing arrhythmic waveforms in 
situations where these were observed at a significantly (P < 0.05) 
higher incidence than in WT controls. Incidences of arrhythmia 
increased both with gene dosage, with effects noticeable in the 
RyR2s/s rather than the RyR2p/s hearts, and following treatment with 
epinephrine (see Figure 1, top panel). Treatment with propranolol 
significantly decreased arrhythmia incidence in epinephrine-treated 
hearts but had no effect in controls. There were no significant dif-
ferences in incidence of arrhythmia between groups treated with 
propranolol. We thus confirm previous reports of increases in the 
Figure 1 | incidences of arrhythmia in WT, RyR2p/s and RyR2p/s hearts. 
Incidences of ventricular arrhythmia occurring in WT (A), RyR2p/s (B) and RyR2p/s 
(C) hearts treated with control solution (a) and with solutions containing 100 nM 
epinephrine (b) and 1 μM epinephrine (c). The top panel shows traces obtained in 
the absence of propranolol; the bottom panel shows data obtained in 
the presence of 100 nM propranolol. Asterisks in the top panel 
indicate situations in which incidence of arrhythmia was significantly 
(P < 0.05) higher than in WT controls; brackets indicate significant 
(P < 0.05) differences in incidence of arrhythmia between other sets 
of conditions.
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found in WT or RyR2p/s
 
hearts. While treatment with propranolol 
tended to increase alternans magnitude when applied to WT hearts 
in the absence of epinephrine, it significantly (P < 0.05) decreased 
alternans magnitude in all other cases.
Alternans magnitude in pooled data from arrhythmic hearts 
was significantly greater than in hearts that did not demonstrate 
arrhythmia (4.2 ± 0.5 ms, n = 55 vs. 2.8 ± 0.3 ms, n = 126; P < 0.05), 
confirming an association between alternans and arrhythmia under 
the experimental conditions studied.
 pharmacological manipulation, RyR2p/s hearts demonstrated 
alternans magnitudes statistically indistinguishable from values 
obtained in WTs. Following treatment with epinephrine, however, 
alternans magnitude was significantly (P < 0.05) greater than seen 
in equivalent groups of WT hearts. RyR2s/s
 
hearts showed signifi-
cantly (P < 0.05) greater alternans magnitudes than either WT 
or RyR2p/s hearts, irrespective of the pharmacological conditions 
studied. Treatment with epinephrine again increased alternans 
magnitude, with values being significantly (P < 0.05) larger than 
Figure 2 | Arrhythmia in WT, RyR2p/s and RyR2p/s hearts. Monophasic action 
potential recordings obtained from WT (A), RyR2p/s (B) and RyR2p/s (C) hearts 
treated with control solution (a) and with solutions containing 100 nM 
epinephrine (b) and 1 μM epinephrine (c). The top panel  shows traces obtained 
in the absence of propranolol; the bottom panel  shows traces obtained in the 
presence of 100 nM propranolol. Traces show arrhythmia where this was 
observed significantly (P < 0.05) more frequently than in WT controls (see 
Figure 1). Vertical lines indicate the timing of stimuli.
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VERP and restitution curve slopes. The present experiments thus 
proceeded to study these parameters, the latter two for the first 
time in RyR2-P2328S mutant hearts.
Alternans and arrhythmia in murine models of a number of 
hereditary (Thomas et al., 2007a,b) and acquired (Sabir et al., 2007) 
arrhythmic disorders have been associated with changes in APD, 
Figure 3 | relationships between alternans magnitude and baseline cycle 
length. Relationships between alternans magnitude, defined as the difference 
between APD (at 90% re-polarization, APD90) for successive odd- and 
even-numbered action potentials, and BCL in WT (A), RyR2p/s (B) and RyR2s/s 
(C) hearts treated with control solution (diamonds) and with solutions containing 
100 nM epinephrine (squares) and 1 μM epinephrine (triangles). The top panel  
shows traces obtained in the absence of propranolol; the bottom panel shows 
traces obtained in the presence of 100 nM propranolol.
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Figure 6 summarizes the maximum values of slopes obtained 
at the shortest BCLs studied.
Maximum slopes obtained from WT hearts under control con-
ditions closely agreed with previous data (Sabir et al., 2008a,b). 
There was no significant difference in restitution curve slope 
between any experimental groups, however. Furthermore, pooled 
data from arrhythmic hearts gave a maximum slope that was not 
significantly different from that obtained from non-arrhythmic 
hearts (0.4 ± 0.2, n = 55 vs. 0.5 ± 0.2, n = 126). Thus alternans 
and arrhythmia were not associated with significant changes in 
the slopes of restitution curves. Thus, in contrast to the results of a 
previous study carried out in models of other hereditary arrhyth-
mic syndromes (Sabir et al., 2008a), alternans and arrhythmia in 
this setting cannot be explained by alterations in the slopes of 
restitution curves.
DISCUSSION
Catecholaminergic polymorphic ventricular tachycardia is a heredi-
tary arrhythmic disorder attributed to mutations that affect the 
cardiac ryanodine receptor (RyR2) (Priori et al., 2001). Ventricular 
arrhythmia in CPVT patients has been associated with alterna-
tions in APD, alternans (Aizawa et al., 2006), a link already well 
established in other situations (Lewis, 1911; Gold et al., 2000; Weiss 
et al., 2006). The present study sought to determine if genetically 
modified mice incorporating a P2328S mutation in the RyR2 gene 
(Goddard et al., 2008), previously established to result in CPVT 
in some patients (Laitinen et al., 2001; Priori et al., 2001), exhibit 
alternans. It then proceeded to determine if such alternans and 
arrhythmia were associated with changes in action potential or 
refractory properties, or in the slopes of restitution curves (Nolasco 
and Dahlen, 1968), as is the case in murine models of other human 
arrhythmic syndromes (Thomas et al., 2007a; Sabir et al., 2008a,b). 
First, APD
90
 was recorded through a wide range of BCLs before 
and after exposure to epinephrine and to propranolol, separately 
and in combination. APD
90
 increased with increasing BCL, as previ-
ously established (Sabir et al., 2007) but did not differ significantly 
between WT, RyR2p/s and RyR2s/s hearts at any BCL. Furthermore, 
epinephrine treatment left APD
90
 unchanged apart from in two 
cases in WT (P < 0.05), but not RyR2p/s or RyR2s/s, hearts. Finally, 
propranolol did not significantly affect APD
90
 at any BCL. These 
observations fully agree with previous observations of electrocardi-
ographic QT interval in patients with CPVT (Priori et al., 2001).
Secondly, VERP values were obtained under the full range of 
experimental conditions studied using an extrasystolic stimulation 
protocol. Neither these genetic nor pharmacological manipulations 
resulted in significant changes in VERP in any case.
Thirdly, recent studies had associated alternans and arrhythmia 
in murine hearts with increases in the slopes of restitution curves 
relating APD
90
 to the preceding diastolic interval (DI), given by 
the difference between the preceding BCL and APD
90
 (Sabir et al., 
2008a,b) (illustrated in Figure 4).
Such curves were constructed using APD
90
 and DI data obtained 
during the dynamic pacing protocol. They could not be derived 
from parameters recorded during treatment with 1 μM epinephrine 
as the high incidence of arrhythmia did not permit acquisition 
of the appropriate data. Their slopes were assessed from fits to a 
simple, mono-exponential growth function of the form:
y = y
0
 + A(1−e−x/τ) (1) (Sabir et al., 2008b)
y representing APD
90
, x representing DI and y
0
 and A and τ 
being constants obtained by least-squares fitting to the experi-
mental values of APD
90
 and DI. Fits were made using a least-
squares method.
Figure 5 shows an example of such a curve obtained from WT 
hearts under control conditions.
The corresponding slopes are then given by:
dy
dx
A x= ⋅ −
τ
τe /
 
(2)
Figure 4 | Cartoon representation of parameters used to construct 
restitution curves.
Figure 5 | Sample restitution curve. Sample curve obtained from WT 
hearts in the absence of pharmacological manipulations. Data were fitted with 
a curve of the form y = y0 + A(1−e−x/τ) where y0 = −11.9 ± 3.6, A = 60.0 ± 2.6, 
τ = 57.8 ± 5.4, χ2 = 0.98 (n = 7).
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Figure 6 | Maximum slopes of restitution curves. Maximum slopes obtained from restitution curves in WT (A), RyR2p/s (B) and RyR2s/s (C) hearts treated with 
control solution (n) and with solution containing 100 nM epinephrine (o), prior to (top panel)  and after (bottom panel) addition of 100 nM propranolol. Maximum 
slopes did not differ significantly between experimental groups.
MAP recordings were obtained from the epicardia of Langendorff-
perfused hearts both heterozygous (RyR2p/s) and homozygous 
(RyR2s/s) for the mutation, as well as from WT controls.
Previous studies conducted on genetically modified murine 
hearts modeling CPVT have used a range of maneuvers to demon-
strate the presence of an arrhythmogenic phenotype. For example, 
Cerrone et al. (2005) used a combination of isoprenaline and caf-
feine. Goddard et al. (2008) later reported the qualitative presence 
of an arrhythmogenic phenotype in catecholamine-treated hearts 
incorporating the RyR2-P2328S mutation during the application of 
both regular and extrasystolic stimulation protocols. In the present 
study arrhythmogenicty was assessed during periods of rapid pac-
ing as part of a dynamic pacing protocol. Results confirmed the 
arrhythmogenic effect of this mutation, as well as demonstrating 
a pro-arrhythmic effect from epinephrine and an anti-arrhythmic 
effect from propranolol, all in full agreement with expectations 
from clinical studies (Priori et al., 2002; Postma et al., 2005).
The experiments then sought to study alternans in these mice. 
Under all genetic and pharmacological conditions studied alternans 
magnitude, defined as the difference in APD between successive 
odd- and even-numbered action potentials, increased as BCL was 
decreased. This is in full agreement with previous work (Walker 
et al., 2003). In general, treatment with epinephrine increased, 
while treatment with propranolol decreased, alternans magnitude. 
Furthermore, RyR2s/s hearts demonstrated significantly larger alter-
nans magnitudes than RyR2p/s hearts or WT controls, in fitting with 
the increased incidences of arrhythmia observed. This represents 
both the first experimental demonstration of alternans occurring 
in the murine heart as a result of exposure to catecholamines and 
the first demonstration of alternans in any experimental model of 
CPVT. Notably alternans magnitude in pooled data from arrhyth-
mic hearts was significantly greater than that from hearts that did 
not demonstrate arrhythmia.
Subsequent experiments examined a possible basis for alternans 
in this setting. A large number of previous studies (Karagueuzian 
et al., 1993; Lee et al., 1996; Koller et al., 1998, 2000; Taggart et al., 
2003; Pak et al., 2004) have associated alternans with steeply sloping 
restitution curves relating APD to the preceding DI (Nolasco and 
Dahlen, 1968). Furthermore, such steeply sloping restitution curves 
have been associated with arrhythmogenicity in humans with the 
Brugada syndrome (Narayan et al., 2007), another hereditary 
arrhythmic syndrome (Antzelevitch et al., 2003). Furthermore, sim-
ilar associations have been made in murine genetic models of both 
the Brugada syndrome and the congenital long-QT syndrome type 
3, as well as in hypokalemic murine hearts (Sabir et al., 2008a,b). 
In this study, however, neither the effect of RyR2-P2328S mutation, 
epinephrine nor propranolol were associated with changes in the 
slopes of restitution curves. Furthermore, the maximum slopes of 
restitution curves did not exceed unity, an established criterion 
for arrhythmogenesis (Nolasco and Dahlen, 1968), under any set 
of experimental conditions studied. Notably alternans has previ-
ously been reported in the absence of steeply sloping restitution 
curves (Pruvot et al., 2004; Goldhaber et al., 2005). In these cases 
alternations in [Ca2+]
i
 has been suggested to affect both the inward 
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